A vital, global collaboration to protect patients from the harm that medicines can cause
The WHO Programme for International Drug Monitoring is a group of more than 150 countries that share the vision of safer and more effective use of medicines. They work nationally and collaborate internationally to monitor and identify the harm caused by medicines, to reduce the risks to patients and to establish worldwide pharmacovigilance standards and systems. UMC has been responsible for the technical and operational aspects of the programme since 1978.
The WHO Programme was created in 1968 to ensure that evidence about harm to patients was collected from as many sources as possible. This would enable individual countries to be alerted to patterns of harm that were emerging across the world and which might not be evident from their local data alone.
Being a member of the WHO Programme brings many benefits and opportunities.
Find out more about the steps needed to join the programme and what it means to be a member.
Member countries have access to a range of services and practical resources to support their technical capacity, communications and outreach.
Learn more about our research department and their expertise.
A web-based data management system available for use by national pharmacovigilance centres.
Learn more about VigiBase – the WHO global database for suspected individual case safety reports.